CONSORT 2025 statement: Updated guideline for reporting randomised trials
Sally Hopewell(University of Oxford), Isabelle Boutron(Inserm), Martin Offringa(Hospital for Sick Children), Lehana Thabane(Impact), Brennan C Kahan(MRC Clinical Trials Unit at UCL), Dawn P. Richards(Robarts Clinical Trials), R. Taylor(University of Oxford), Nita Bhandari, Sophie Staniszewska(University of Warwick), Philippe Ravaud(Inserm), Jesse A. Berlin(Janssen (Belgium)), An‐Wen Chan(World Health Organization), Elizabeth Loder(Brigham and Women's Hospital), Runcie C.W. Chidebe(University of Miami), Kenneth F. Schulz(University of North Carolina at Chapel Hill), Diana Elbourne(London School of Hygiene & Tropical Medicine), Ian R. White(MRC Clinical Trials Unit at UCL), Steven N. Goodman(Stanford University), Gary S. Collins(NIHR Birmingham Biomedical Research Centre), Andrew Farmer(University of Oxford), Dean Fergusson(Ottawa Hospital), Steff Lewis(University of Edinburgh), David Moher(University of Ottawa), Sarah E Lamb(University of Exeter), John P. A. Ioannidis(Innovative Research (United States)), Sunita Vohra(University of Alberta), Nancy J. Butcher(University of Toronto), David L. Schriger(University of California, Los Angeles), Nandi Siegfried(South African Medical Research Council), Marion Campbell(Hairmyres Hospital), Frank W. Rockhold(Amyloidosis Foundation), Tammy Hoffmann(Bond University), Rachel L Knowles(Great Ormond Street Hospital), David Torgerson(University of York), Robert M. Golub(Northwestern University), Michael Berkwits, R. Tunn(Oxford BioMedica (United Kingdom)), Asbjørn Hróbjartsson(University of Southern Denmark), Rakesh Aggarwal(Sanjay Gandhi Post Graduate Institute of Medical Sciences)
Cited by 111